Page URL:

Aggressive prostate cancer gene identified

3 September 2018
Appeared in BioNews 965

Finnish researchers have identified two possible mutations in one gene that are both correlated with prostate cancer.

Prostate cancer is the sixth most common cause of male cancer-related death worldwide. Heritability is estimated to make up 57 percent of the risk but few biomarkers are available to diagnose aggressive disease. Identifying relevant mutations could improve diagnostic tests.

'Those with the more aggressive forms of prostate cancer have the bleakest outcome but if we can devise tests to diagnose them early on, we can do more to ensure they receive the best possible treatment,' Helen Rippon, chief executive of the Worldwide Cancer Research charity, which helped fund the study, told the Times.

Over 100 susceptibility mutations had already been identified in the human genome, but only a few have been shown to affect disease severity and outcome. 

In recent research, published in the International Journal of Cancer, a Finnish research team sequenced a gene called ANO7 that they suspected was involved in prostate cancer. The researchers used DNA samples from over 1700 Finnish prostate cancer patients alongside samples from a similar number of unaffected men. The results were validated against a larger sample group of over 5000 Swedish and Norwegian patients and 1400 further controls.

Within ANO7, the scientists found one mutation that correlated with an increased risk of developing prostate cancer, as well as disease severity. A second mutation correlated with shorter survival time. 

Additionally, 22 prostate tumour samples were analysed for ANO7 gene expression. Gene expression was found to be highly raised in prostate cancer tumours compared with normal prostate tissue, and higher expression correlated with patient mortality rate. 

'Genetic testing for ANO7 could help identify these patients sooner and may bring new opportunities for precision oncology in prostate cancer,' said lead author Professor Johanna Schleutker of the Institute of Biomedicine of the University of Turku. 

One limitation of the study is that the subjects were all Northern European Caucasian patients. The researchers suggested that people of other ethnic backgrounds should also be studied before screening for ANO7 can be recommended. 

ANO7 is associated with aggressive prostate cancer
International Journal of Cancer |  30 August 2018
Gene test offers new hope in prostate cancer treatment
The Times |  30 August 2018
New genetic marker could help diagnose aggressive prostate cancer
University of Turku |  30 August 2018
New genetic marker could improve diagnosis of prostate cancer
News medical |  30 August 2018
11 January 2021 - by Dr Melania Montes P√©rez 
Black men present genetic variations that make them more vulnerable than white men to developing prostate cancer research revealed...
13 May 2019 - by Dr Charlott Repschlager 
A mutation that raises a prostate cancer patient's risk of death by threefold has been discovered...
12 November 2018 - by Isobel Steer 
A test has been developed that can detect at least eight different types of cancer, by characterising the size of tumour DNA fragments in the blood...
22 October 2018 - by Isobel Steer 
Researchers have identified a DNA methylation signature that can identify aggressive prostate cancer, with up to 92 percent accuracy...
28 August 2018 - by Dr Katie Howe 
Genome sequencing has been used to shed light on the genetic causes of breast cancer in African woman and develop a model to predict breast cancer risk...
28 August 2018 - by Martha Henriques 
Electronic cigarettes may alter the DNA in users' mouths, potentially increasing their risk of cancer if the damage is not repaired, a preliminary study has found...
6 August 2018 - by Dr James Heather 
Australian researchers have developed a new kind of anti-cancer drug, which halted cancer cells in their tracks in mice...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.